Mutual of America Capital Management LLC Buys 28,504 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV)

Mutual of America Capital Management LLC increased its position in shares of Roivant Sciences Ltd. (NASDAQ:ROIV) by 23.4% during the 4th quarter, Holdings Channel reports. The fund owned 150,363 shares of the company’s stock after buying an additional 28,504 shares during the quarter. Mutual of America Capital Management LLC’s holdings in Roivant Sciences were worth $1,689,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of ROIV. Citigroup Inc. increased its position in shares of Roivant Sciences by 1,803.6% in the 1st quarter. Citigroup Inc. now owns 5,749 shares of the company’s stock valued at $28,000 after buying an additional 5,447 shares in the last quarter. Royal Bank of Canada raised its position in shares of Roivant Sciences by 60,550.0% during the first quarter. Royal Bank of Canada now owns 6,065 shares of the company’s stock worth $30,000 after purchasing an additional 6,055 shares during the period. FNY Investment Advisers LLC bought a new position in shares of Roivant Sciences during the 4th quarter valued at about $33,000. Allspring Global Investments Holdings LLC acquired a new position in shares of Roivant Sciences in the 3rd quarter valued at approximately $44,000. Finally, Jane Street Group LLC bought a new stake in Roivant Sciences during the 3rd quarter worth approximately $48,000. Institutional investors and hedge funds own 64.76% of the company’s stock.

Insider Buying and Selling at Roivant Sciences

In other news, COO Eric Venker sold 96,950 shares of Roivant Sciences stock in a transaction dated Friday, February 9th. The shares were sold at an average price of $10.92, for a total value of $1,058,694.00. Following the completion of the transaction, the chief operating officer now owns 532,207 shares of the company’s stock, valued at approximately $5,811,700.44. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 4.60% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on ROIV. Bank of America lifted their price target on shares of Roivant Sciences from $11.00 to $12.00 and gave the company a “neutral” rating in a research note on Tuesday, January 2nd. Truist Financial reaffirmed a “buy” rating and issued a $23.00 target price on shares of Roivant Sciences in a research note on Monday, March 25th. The Goldman Sachs Group increased their target price on Roivant Sciences from $16.00 to $18.00 and gave the stock a “buy” rating in a report on Wednesday, April 3rd. TheStreet upgraded Roivant Sciences from a “d” rating to a “c+” rating in a research note on Tuesday, February 13th. Finally, HC Wainwright upped their price target on Roivant Sciences from $17.00 to $18.00 and gave the stock a “buy” rating in a research report on Wednesday, April 3rd. One investment analyst has rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $16.90.

Roivant Sciences Stock Performance

Shares of NASDAQ ROIV opened at $10.46 on Monday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 27.79 and a current ratio of 27.79. The stock has a 50 day moving average price of $10.95 and a 200 day moving average price of $10.35. The stock has a market capitalization of $8.43 billion, a PE ratio of 2.01 and a beta of 1.34. Roivant Sciences Ltd. has a 52 week low of $8.06 and a 52 week high of $13.24.

Roivant Sciences (NASDAQ:ROIV) last announced its quarterly earnings data on Tuesday, February 13th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.07. Roivant Sciences had a negative return on equity of 33.38% and a net margin of 3,624.14%. The company had revenue of $37.14 million for the quarter, compared to analysts’ expectations of $30.72 million. Analysts predict that Roivant Sciences Ltd. will post -1.36 earnings per share for the current fiscal year.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.